Exagen earnings release, May 11, 2026

Exagen Inc. (XGN) · Form 8-K, Item 2.02 · Filed · SEC filing

Exagen Inc. Reports First Quarter 2026 Results

Delivers record total revenue and AVISE

(R)

CTD average selling price

May 11, 2026

Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

First Quarter 2026 Highlights:

• Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025.

• Grew AVISE CTD test volume 10% compared to first quarter 2025.

• Expanded AVISE CTD trailing-twelve-month ASP to $444 per test, an increase of $25 per test, or 6% compared to first quarter 2025.

• Delivered an adjusted EBITDA loss of $2.2 million, an improvement of 14% compared to first quarter 2025.

• Ended the quarter with approximately $22 million in cash and cash equivalents, ahead of expectations and consistent with long-standing strategy to hold claims in the first quarter.

“First quarter results establish a solid start to 2026, reflecting our team’s disciplined execution and effective revenue cycle management,” said John Aballi, President and CEO.

“Exagen is uniquely committed to providing clarity for autoimmune patients and confidence for clinicians.

We have built a foundation to expand our reach and advance innovation in a market with significant unmet need.”

2026 Guidance

The Company continues to expect full-year 2026 revenue of $70 million to $73 million.

Conference Call

A conference call to review first quarter financial results is scheduled for today, May 11, 2026, at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing (877) 407-0890 (U.S.), or +1 (201) 389-0918 (international). Additionally, a link to a live webcast of the call will be available in the Investor Relations section of Exagen's website at investors.exagen.com.

Participants are asked to join a few minutes prior to the call to register for the event.

A replay of the conference call will be available until May 25, 2026. Interested parties may access the replay by dialing (877) 660-6853 (U.S.) or +1 (201) 612-7415 (international) using passcode 13759736. A link to the replay of the webcast will also be available in the Investor Relations section of Exagen's website.

Use of Non-GAAP Financial Measures (UNAUDITED)

In addition to the financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release contains the metric adjusted EBITDA, which is not calculated in accordance with GAAP and is a non-GAAP financial measure.

Adjusted EBITDA is defined as net loss adjusted for interest income (expense), income tax expense (benefit), depreciation and amortization expense, stock‑based compensation expense, change in fair value of warrant liability, and certain other non‑cash, unusual or non‑recurring items, including, for example, losses on extinguishment of debt and changes in the fair value of warrant liabilities; we do not exclude normal, recurring, cash operating expenses from this measure.

Such items could have a significant impact on the calculation of GAAP net loss.

Exagen uses adjusted EBITDA internally because the company believes these metrics provide useful supplemental information in assessing its operating performance reported in accordance with GAAP. Exagen believes adjusted EBITDA may enhance an evaluation of the operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses the company believes are not indicative of the ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes.

This non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with the financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that Exagen may exclude for purposes of these non-GAAP financial measures, and the company may in the future cease to exclude items that it has historically excluded for purposes of these non-GAAP financial measures. Likewise, Exagen may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by the company in this press release and the accompanying reconciliation table have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures.

A reconciliation of net loss to non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release.

About Exagen... (truncated)ise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit

Exagen.com or follow Exagen on

LinkedIn.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Unaudited. In thousands, except ASP data.Revenue17,30615,498
Unaudited. In thousands, except ASP data.Gross margin59.0%58.9%
Unaudited. In thousands, except ASP data.Operating expenses13,61912,488
Unaudited. In thousands, except ASP data.Operating loss-3,414-3,365
Unaudited. In thousands, except ASP data.Net loss-3,967-3,752
Unaudited. In thousands, except ASP data.Adjusted EBITDA-2,160-2,508
Unaudited. In thousands, except ASP data.Trailing-twelve-month average selling price (ASP)444419
Unaudited. In thousands, except ASP data.Cash and cash equivalents21,51311,194

Income Statement

Three Months Ended March 31, — (in thousands, except share and per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue17,30615,498
Cost of revenue7,1016,375
Gross margin10,2059,123
Operating expenses:Selling, general and administrative expenses12,06611,204
Operating expenses:Research and development expenses1,5531,284
Operating expenses:Total operating expenses13,61912,488
Operating expenses:Loss from operations-3,414-3,365
Operating expenses:Interest expense-1,267-545
Operating expenses:Change in fair value of warrant liability882
Operating expenses:Other income (expense), net-132158
Operating expenses:Loss before income taxes-3,931-3,752
Operating expenses:Income tax benefit-36
Operating expenses:Net loss-3,967-3,752
Operating expenses:Net loss per share, basic and diluted-0.17-0.2
Operating expenses:Weighted-average number of shares used to compute net loss per share, basic and diluted23,854,99718,557,390

Income Statement

Three Months Ended March 31, (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net loss-3,967-3,752
Other (income) expense132-158
Interest expense1,267545
Change in fair value of warrant liability-882
Income tax expense (benefit)36
Depreciation and amortization expense599440
Stock-based compensation expense655417
Adjusted EBITDA (Non-GAAP)-2,160-2,508

Balance Sheet

March 31, 2026 — (in thousands, except share and per share amounts)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents21,51332,220
Current assets:Accounts receivable, net15,77310,855
Current assets:Prepaid expenses and other current assets6,2975,818
Current assets:Total current assets43,58348,893
Current assets:Property and equipment, net6,6116,938
Current assets:Operating lease right-of-use assets1,1791,435
Current assets:Other assets584756
Current assets:Total assets51,95758,022
Current liabilities:Accounts payable4,1594,153
Current liabilities:Accrued and other current liabilities4,7726,327
Current liabilities:Deferred revenue681675
Current liabilities:Finance lease liabilities, current1,1131,135
Current liabilities:Operating lease liabilities, current1,2591,226
Current liabilities:Borrowings, current580643
Current liabilities:Total current liabilities12,56414,159
Current liabilities:Borrowings, non-current, net of discounts and debt issuance costs22,29122,264
Current liabilities:Finance lease liabilities, non-current1,7921,960
Current liabilities:Operating lease liabilities, non-current111438
Current liabilities:Warrant liability7671,752
Current liabilities:Total liabilities37,52540,573
Stockholders' equity:Common stock, $0.001 par value; 200,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 24,088,057 and 22,911,575 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively2423
Stockholders' equity:Additional paid-in capital332,657331,708
Stockholders' equity:Accumulated deficit-318,249-314,282
Stockholders' equity:Total stockholders' equity14,43217,449
Stockholders' equity:Total liabilities and stockholders' equity51,95758,022
Full release

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies, positioning, and ambitions; evaluations and judgments regarding financial results and the potential implications of those results, potential future financial and business performance, including any improvements to adjusted EBITDA, ASP, net loss and potential profitability; the potential utility and effectiveness of Exagen’s services and testing solutions; the anticipated benefits of and adoption trajectory for Exagen's recently launched biomarkers; the impact of Exagen's revenue cycle management strategy on the timing of collections and cash burn; potential stockholder value and growth and full-year 2026 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; the potential effects of inflation and tariffs on Exagen’s margins; and changes in laws and regulations related to Exagen’s regulatory requirements. Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; and ability to obtain additional funding; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 10, 2026, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investors:

Tina Jacobsen, CFA

Exagen Inc. ir@exagen.com

Exagen Inc.

Unaudited Condensed Statements of Operations

(in thousands, except share and per share amounts)

Exagen Inc.

Unaudited Condensed Balance Sheets

(in thousands, except share and per share amounts)

Exagen Inc.

Reconciliation of Non-GAAP Financial Measures (UNAUDITED)

The table below presents the reconciliation of adjusted EBITDA, which is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding Exagen's use of non-GAAP financial measures.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Exagen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.